263 related articles for article (PubMed ID: 12691141)
1. Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013.
Silver RT; Peterson BL; Szatrowski TP; Powell BL; Stock W; Carroll AJ; Bloomfield CD; Schiffer CA; Larson RA
Leuk Lymphoma; 2003 Jan; 44(1):39-48. PubMed ID: 12691141
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
Kantarjian HM; O'Brien S; Smith TL; Rios MB; Cortes J; Beran M; Koller C; Giles FJ; Andreeff M; Kornblau S; Giralt S; Keating MJ; Talpaz M
J Clin Oncol; 1999 Jan; 17(1):284-92. PubMed ID: 10458244
[TBL] [Abstract][Full Text] [Related]
3. Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase.
Giles FJ; Kantarjian H; O'Brien S; Rios MB; Cortes J; Beran M; Koller C; Keating M; Talpaz M
Leuk Lymphoma; 2001 Apr; 41(3-4):309-19. PubMed ID: 11378543
[TBL] [Abstract][Full Text] [Related]
4. Hematological and cytogenetic response of interferon alpha 2b alone and combined interferon alpha plus cytarabine as a first-line treatment in chronic myeloid leukemia.
Tóthová E; Fricová M; Kafková A; Stecová N; Guman T; Raffac S; Hlebasková M
Neoplasma; 2000; 47(2):125-8. PubMed ID: 10985480
[TBL] [Abstract][Full Text] [Related]
5. Results of a phase II trial testing interferon-alpha 2b and cytarabine in children and adolescents with chronic myelogenous leukemia.
Millot F; Guilhot J; Nelken B; Leblanc T; Leverger G; Bernard F; Gandemer V; Béhard C; Berger C; Cornu G; Duchène S; Guilhot F
Pediatr Blood Cancer; 2006 Oct; 47(5):555-9. PubMed ID: 16317737
[TBL] [Abstract][Full Text] [Related]
6. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM
Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside.
Garcia-Manero G; Talpaz M; Giles FJ; Cortes J; Faderl S; O'Brien S; Thomas D; Verstovsek S; Beth Rios M; Shan J; Ferrajoli A; Wierda W; Kantarjian HM
Cancer; 2003 Jun; 97(12):3010-6. PubMed ID: 12784336
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
O'Brien S; Talpaz M; Cortes J; Shan J; Giles FJ; Faderl S; Thomas D; Garcia-Manero G; Mallard S; Beth M; Koller C; Kornblau S; Andreeff M; Murgo A; Keating M; Kantarjian HM
Cancer; 2002 Apr; 94(7):2024-32. PubMed ID: 11932905
[TBL] [Abstract][Full Text] [Related]
9. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583.
Ozer H; George SL; Schiffer CA; Rao K; Rao PN; Wurster-Hill DH; Arthur DD; Powell B; Gottlieb A; Peterson BA; Rai K; Testa JR; LeBeau M; Tantravahi R; Bloomfield CD
Blood; 1993 Nov; 82(10):2975-84. PubMed ID: 8219189
[TBL] [Abstract][Full Text] [Related]
10. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group.
Guilhot F; Chastang C; Michallet M; Guerci A; Harousseau JL; Maloisel F; Bouabdallah R; Guyotat D; Cheron N; Nicolini F; Abgrall JF; Tanzer J
N Engl J Med; 1997 Jul; 337(4):223-9. PubMed ID: 9227927
[TBL] [Abstract][Full Text] [Related]
11. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
Druker BJ; Guilhot F; O'Brien SG; Gathmann I; Kantarjian H; Gattermann N; Deininger MW; Silver RT; Goldman JM; Stone RM; Cervantes F; Hochhaus A; Powell BL; Gabrilove JL; Rousselot P; Reiffers J; Cornelissen JJ; Hughes T; Agis H; Fischer T; Verhoef G; Shepherd J; Saglio G; Gratwohl A; Nielsen JL; Radich JP; Simonsson B; Taylor K; Baccarani M; So C; Letvak L; Larson RA;
N Engl J Med; 2006 Dec; 355(23):2408-17. PubMed ID: 17151364
[TBL] [Abstract][Full Text] [Related]
12. Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon alpha-2b for the treatment of chronic myelogenous leukemia patients in chronic phase.
Maloisel F; Guerci A; Guyotat D; Ifrah N; Michallet M; Reiffers J; Tertain G; Blanc M; Bauduer F; Brière J; Abgrall JF; Pegourie-Bandelier B; Solary E; Cambier N; Coso D; Vilque JP; Delain M; Harousseau JL; Rousselot P; Belhadj K; Morice P; Attal J; Chabin M; Chastang C; Guilhot J; Guilhot F;
Leukemia; 2002 Apr; 16(4):573-80. PubMed ID: 11960335
[TBL] [Abstract][Full Text] [Related]
13. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP;
N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335
[TBL] [Abstract][Full Text] [Related]
14. Combined interferon alfa-2a and cytosine arabinoside as first-line treatment for chronic myeloid leukemia.
Arthur CK; Ma DD
Acta Haematol; 1993; 89 Suppl 1():15-21. PubMed ID: 8475667
[TBL] [Abstract][Full Text] [Related]
15. Interferon-alpha-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia.
Mollee P; Arthur C; Hughes T; Januszewicz H; Grigg A; Bradstock K; Wolf M; Gibson J; Schwarer AP; Spencer A; Browett P; Hawkins T; Seldon M; Herrmann R; Watson A; Seymour JF; Martin N; Shina S; Low C; Wright S; Rodwell R; Coulston J; Morton J; Blacklock H; Taylor D; Taylor KM
Ann Oncol; 2004 Dec; 15(12):1810-5. PubMed ID: 15550587
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and toxicity of IFN-alpha2b combined with cytarabine in chronic myelogenous leukaemia.
Lindauer M; Domkin D; Döhner H; Kolb HJ; Neubauer A; Huhn D; Kreiter H; Koch B; Huber C; Aulitzky W; Fischer T
Br J Haematol; 1999 Sep; 106(4):1013-9. PubMed ID: 10520005
[TBL] [Abstract][Full Text] [Related]
17. [The 6M 12M trial--study of the effectivess and tolerance of treatment in chronic myeloid leukaemia with a combination of interferon alfa and cytarabine].
Tóthová E; Fricová M; Stecová N; Svorcová E; Guman T; Rraffac S; Kafková A; Hlebasková M
Vnitr Lek; 2000 Jul; 46(7):391-4. PubMed ID: 15635799
[TBL] [Abstract][Full Text] [Related]
18. Alpha-interferon in combination with cytarabine in children with Philadelphia chromosome-positive chronic myeloid leukemia.
Millot F; Brice P; Philippe N; Thyss A; Demeoq F; Wetterwald M; Boccara JF; Vilque JP; Guyotat D; Guilhot J; Guilhot F
J Pediatr Hematol Oncol; 2002 Jan; 24(1):18-22. PubMed ID: 11902732
[TBL] [Abstract][Full Text] [Related]
19. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine.
Kantarjian HM; Keating MJ; Estey EH; O'Brien S; Pierce S; Beran M; Koller C; Feldman E; Talpaz M
J Clin Oncol; 1992 May; 10(5):772-8. PubMed ID: 1569449
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013.
Hensley ML; Peterson B; Silver RT; Larson RA; Schiffer CA; Szatrowski TP
J Clin Oncol; 2000 Mar; 18(6):1301-8. PubMed ID: 10715301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]